Immune Booster Cells Show Promise After Checkpoint Blockers in Liver Cancer

Advanced hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the most formidable challenges in clinical oncology. Even after the arrival of immune checkpoint inhibitors, drugs that unleash the immune system by releasing the molecular brakes on T cells, only a minority of patients with advanced disease experience meaningful tumor shrinkage. Now, a preliminary clinical study from Taiwan suggests that a carefully sequenced combination, a short course of checkpoint blockade followed by infusions of a patient’s own dendritic cells, may substantially deepen the immune response and improve outcomes in this hard-to-treat population.

The study, conducted by a surgical and oncology team at Chang-Gung Memorial Hospital and Chang-Gung University College of Medicine in Taoyuan, enrolled twenty-four patients with advanced hepatocellular carcinoma classified under the Barcelona Clinic Liver Cancer staging system. Five of the participants were in stage B with large or infiltrating tumors, while nineteen were in stage C, the most advanced category in the classification. The therapeutic strategy was deliberately two-phased. First, patients received between three and six courses of a checkpoint inhibitor, either nivolumab at 3 milligrams per kilogram of body weight or pembrolizumab at 2 milligrams per kilogram. Both agents block the PD-1 receptor, a checkpoint molecule that tumors exploit to disable attacking T cells. Then, after this priming phase, patients received three courses of autologous dendritic cell therapy, using immune cells harvested from their own peripheral blood monocytes, grown in the laboratory, and loaded with lysate prepared from the patient’s own tumor tissue.

The logic behind this sequence rests on a well-established principle of cancer immunology. Checkpoint inhibitors work best when the immune system has already recognized the tumor and mounted a T cell response against it, but many patients with hepatocellular carcinoma never generate such a response in the first place. Dendritic cells are the professional antigen-presenting cells of the immune system, the sentinels whose job is to capture foreign or abnormal proteins, process them into peptide fragments, and display those fragments to naive T cells in lymph nodes, thereby initiating targeted cytotoxic immunity. By pulsing laboratory-expanded dendritic cells with tumor lysate, the researchers aimed to teach each patient’s immune system to recognize the specific antigens carried by their own cancer. The preceding checkpoint blockade was intended to create a permissive environment, preventing newly activated tumor-specific T cells from being shut down by PD-1 signaling within the tumor microenvironment.

The results, published open access in the journal Cancer Immunology, Immunotherapy, are striking for a preliminary single-arm study. After the short course of checkpoint inhibitor therapy alone, the objective response rate, meaning the proportion of patients whose tumors shrank measurably by the modified Response Evaluation Criteria in Solid Tumors, was 16.7 percent, with a disease control rate of 70.8 percent. After the subsequent dendritic cell therapy, the objective response rate more than doubled to 41.7 percent, while disease control, which combines partial responses with stable disease, reached 75.0 percent. In other words, the addition of the dendritic cell phase converted a substantial fraction of patients whose disease had merely stabilized, or had not responded at all, into genuine responders.

Survival figures reinforced the impression of clinical benefit. Across all twenty-four patients, the median overall survival reached 36 months, an exceptional figure for advanced hepatocellular carcinoma, a disease in which historical median survival without effective systemic therapy was measured in months. The one-year overall survival rate was 87.5 percent, the two-year rate 75.0 percent, and the three-year rate 45.8 percent. Nearly half of the patients in this advanced-stage cohort were still alive three years after starting the sequential regimen, a result that, if confirmed in larger controlled trials, would represent a meaningful shift in the natural history of the disease.

One of the most intriguing findings of the study concerns a simple blood test that is routinely available in any hospital. The researchers found that patients who achieved an objective response after dendritic cell therapy had a significantly lower neutrophil-to-lymphocyte ratio before starting the dendritic cell phase than patients who did not respond, a difference that reached statistical significance with a p value of 0.028. The neutrophil-to-lymphocyte ratio, or NLR, is a widely used surrogate marker of systemic inflammation. A high ratio is thought to reflect an immune milieu dominated by neutrophils and inflammatory signaling, conditions that are associated with immunosuppression, tumor progression, and resistance to immunotherapy. A low ratio, by contrast, suggests a lymphocyte-rich environment in which adoptively transferred, tumor-primed dendritic cells are more likely to find receptive T cells to activate. If validated, this finding could give clinicians a cheap and rapid biomarker for selecting patients most likely to benefit from the dendritic cell phase of treatment.

Seven of the patients received nivolumab and seventeen received pembrolizumab before the dendritic cell infusions, and the study did not report a meaningful divergence between the two checkpoint inhibitors in this setting, which is consistent with their similar mechanisms of action. The dendritic cell product itself was manufactured in the Cell Processing Unit of the Chang-Gung Memorial Hospital Cell Therapy Center, a facility dedicated to producing patient-specific cellular therapeutics under controlled conditions. The use of tumor lysate rather than a single defined antigen is a deliberate design choice. Hepatocellular carcinoma is a heterogeneous disease, particularly in the context of chronic hepatitis B or C infection and cirrhosis, and no universal tumor antigen has been identified. Loading dendritic cells with the full repertoire of antigens from an individual patient’s tumor allows the immune system to mount a polyclonal response against multiple targets simultaneously, potentially reducing the chance that the cancer can escape by downregulating a single antigen.

Safety considerations are central to any cellular therapy, and the sequential approach appears to have been tolerated acceptably in this cohort. Immune-related adverse effects, the characteristic toxicities of checkpoint blockade arising from immune attack on healthy tissues, are a known risk of the priming phase, and limiting the checkpoint inhibitor course to three to six cycles may help contain cumulative toxicity. The dendritic cell phase, which uses the patient’s own cells pulsed with autologous tumor material, is generally regarded as having a favorable safety profile compared with more aggressive cellular therapies such as engineered T cell products, because the cells are not directly cytotoxic and carry no risk of uncontrolled expansion. The study was supported by a Chang-Gung Research Grant, and the authors declared no conflicts of interest.

The authors themselves are careful to frame the work as preliminary. The study involved a small number of patients, lacked a randomized control arm, and was conducted at a single institution with an integrated cell therapy infrastructure that is not widely available. Selection factors, including the patients’ underlying liver function, prior treatments such as transcatheter arterial embolization or tyrosine kinase inhibitors, and tumor biology, may all have influenced the outcomes. The researchers explicitly state that a large-scale study is needed in the future before the sequential regimen can be considered a standard of care. Nonetheless, the magnitude of the improvement in response rate, from under 17 percent after checkpoint blockade alone to nearly 42 percent after the dendritic cell phase, provides a compelling signal that the two modalities act synergistically rather than redundantly.

The broader significance of the study lies in its timing. Immunotherapy for hepatocellular carcinoma has advanced rapidly, with checkpoint inhibitor combinations now front-line options, yet the majority of patients still fail to respond, and the liver’s uniquely immunosuppressive environment remains a stubborn barrier. Therapeutic dendritic cell vaccines have been pursued for decades with mixed results, and this trial suggests that the order of operations matters: priming the system with checkpoint release before delivering antigen-loaded dendritic cells may succeed where either approach alone falls short. As personalized cell manufacturing becomes more routine and biomarkers such as the neutrophil-to-lymphocyte ratio help identify likely responders, the strategy of sequencing checkpoint blockade with dendritic cell therapy could move from a promising experiment to a practical weapon against one of the world’s deadliest cancers.

Subject of Research: Sequential immunotherapy combining immune checkpoint inhibitors and autologous dendritic cell therapy for advanced hepatocellular carcinoma

Article Title: Sequential therapy with immune checkpoint inhibitors and dendritic cells for advanced hepatocellular carcinoma

Article References: Lee, W.-C., Wang, Y.-C., Wu, T.-H., Lai, Y., Hung, H.-C., Lee, J.-C., Cheng, C.-H., Lee, C.-F., Wu, T.-J., Chou, H.-S., & Chan, K.-M. (2026). Sequential therapy with immune checkpoint inhibitors and dendritic cells for advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04583-w

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04583-w

Keywords: hepatocellular carcinoma, immune checkpoint inhibitors, dendritic cells, immunotherapy, nivolumab, pembrolizumab, cell therapy, neutrophil-to-lymphocyte ratio, BCLC staging, liver cancer, clinical trial, cancer immunology